Age: 62 Director Since 2002
The company has return on total asset (ROA) of (7.89) % which means that it has lost $7.89 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (25.16) % meaning that it generated substantial loss on money invested by shareholders.
Entity SummaryGenmab A/S, a biotechnology company, engages in the development of human antibody therapeutics for the potential treatment of cancer. Genmab A-S [GNMSF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Filter other
Genmab price boundaries
Promote Genmab and Karsten Pedersen